Clinical trials: Adult Depression
Major Depressive Disorder
Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults
The purpose of the study is to evaluate long-term safety and tolerability of Vortioxetine over a period of 52 weeks in patients with Major Depressive Disorder (MDD) having completed 8-week acute treatment.
- Trial name
- NCT00694304
- Testing
- Vortioxetine (Lu AA21004)
- Volunteers
- 535 people
- Sponsor
- H. Lundbeck A/S
Depression, Back Pain
ADAPT: Addressing Depression and Pain Together
The primary question addressed by this study is: Using a stepped care approach in primary care, what is the value of the combination of an antidepressant medication (Venlafaxine) and psychotherapy for seniors living with…
- Trial name
- ADAPT (NCT01124188)
- Testing
- Higher-dose venlafaxine, Supportive management, Problem Solving Therapy for Depression and Pain
- Where
- United States
- Volunteers
- 263 people
- Sponsor
- University of Pittsburgh
Major Depressive Disorder
Escitalopram in Adult Patients With Major Depressive Disorder
This is a short-term study to evaluate the efficacy, safety, and tolerability of escitalopram in adult patients (18 to 65 years of age) with moderate to severe depression.
- Trial name
- NCT00668525
- Testing
- Escitalopram
- Where
- 45 sites in United States
- Volunteers
- 877 people
- Sponsor
- Forest Laboratories
Depression, Postpartum
A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)
The purpose of this study is to determine if treatment with SAGE-217 reduces depressive symptoms in females with severe postpartum depression (PPD) as compared to placebo.
- Trial name
- NCT04442503
- Testing
- SAGE-217
- Where
- 82 sites in United States, Spain and 1 more
- Volunteers
- 200 people
- Sponsor
- Biogen
Depressive Disorder, Major
Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder
The purpose of this study is to evaluate the effects of Lu AA21004, once daily (QD), on cognitive dysfunction in patients with major depressive disorder.
- Trial name
- NCT01564862
- Testing
- vortioxetine (Lu AA21004), Duloxetine
- Where
- 92 sites in United States, Bulgaria and 5 more
- Volunteers
- 602 people
- Sponsor
- Takeda
Major Depressive Disorder
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms.
- Trial name
- NCT01435759
- Testing
- Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg
- Where
- 82 sites in United States, Argentina and 3 more
- Volunteers
- 1,197 people
- Sponsor
- Shire
Depression, Depression in Old Age
Trial to Test Effectiveness of Depression Intervention for Mistreated Older Adults
The investigators developed EM/PROTECT, a behavioral intervention for depressed EM (elderly mistreatment) victims, to work in synergy with EM mistreatment resolution services that provide safety planning, support services, and…
- Conditions
- Depression, Depression in Old Age, Elder Abuse, Anxiety
- Trial name
- NCT04258579
- Testing
- PROTECT with Technology Augmentation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Weill Medical College of Cornell University
Depression in Old Age
PEERS Plus mHealth Enhanced Peer Support
The goal of this intervention study is to design and learn whether peer support that is delivered through video chats and texts can decrease depression among older adults.
- Trial name
- Peers plus (NCT05611996)
- Testing
- Peers plus
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Massachusetts General Hospital
Depressive Disorder, Major
Clinical Study to Test a New Drug to Treat Major Depression
In this randomized, double-blind, multi-centre, placebo controlled, exploratory, adaptive design study, the antidepressant and plasma cytokine lowering effects of the GW856553 will be investigated in adult subjects diagnosed with…
- Trial name
- PKI113009 (NCT00976560)
- Testing
- GW856553
- Where
- 21 sites in United States, Bulgaria and 3 more
- Volunteers
- 128 people
- Sponsor
- GlaxoSmithKline
Covid19, Mental Health
Mental Health Among Patients, Providers, and Staff During the COVID-19 Era
The Mental Health Among Patients, Providers, and Staff (MHAPPS) Study is designed to study how the COVID-19 pandemic has affected mental health and wellbeing, and how to support mental health while minimizing the burden on the…
- Trial name
- MHAPPS (NCT04700137)
- Testing
- Caring Contacts Plus Introductory Phone Call (CC+), Caring Contacts without an introductory phone call (CC)
- Where
- United States
- Volunteers
- 666 people
- Sponsor
- St. Luke's Health System, Boise, Idaho
Major Depressive Disorder
Trial to Evaluate the Effectiveness of a Digital Therapeutics in Adults Diagnosed With Major Depressive Disorder
This study compares the effectiveness of 2 digital therapeutics in adult participants diagnosed with major depressive disorder (MDD) who are on antidepressant therapy (ADT) monotherapy for the treatment of depression.
- Trial name
- MIRAI (NCT04770285)
- Testing
- CT-152 - Digital Therapeutic
- Where
- United States
- Volunteers
- 386 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depressive Disorder, Major, Anhedonia
A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in adult participants with major depressive disorder (MDD) with…
- Trial name
- VENTURA-1 (NCT05455684)
- Testing
- Aticaprant
- Where
- 120 sites in United States, Argentina and 11 more
- Volunteers
- 513 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Vilazodone for Treatment of Geriatric Depression
The purpose of this study is to examine the effects of vilazodone for the treatment of depression in older adults.
- Trial name
- NCT01608295
- Testing
- Vilazodone; Viibryd, Paroxetine; Paxil
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of California, Los Angeles
Major Depressive Disorder With Anxious Distress
A Study of JNJ-61393215 in the Treatment of Depression
The purpose of this study is to evaluate the efficacy of JNJ-61393215 as adjunctive treatment compared to adjunctive placebo, as assessed by the change from baseline to week 6 on a 17-item Hamilton Depression Rating Scale…
- Trial name
- NCT04080752
- Testing
- JNJ-61393215
- Where
- 35 sites in United States, Moldova and 3 more
- Volunteers
- 222 people
- Sponsor
- Janssen Research & Development, LLC
Treatment Outcome
Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction
The purpose of this study is to evaluate the effects of Vortioxetine (Lu AA21004), once daily (QD), compared with escitalopram on sexual functioning.
- Trial name
- NCT01364649
- Testing
- Vortioxetine, Escitalopram
- Where
- 62 sites in United States, Canada
- Volunteers
- 447 people
- Sponsor
- Takeda
Major Depressive Disorder
Trial of Levomilnacipran in Geriatric Depression
The purpose of this study is to examine the effects of levomilnacipran (FETZIMA) compared to placebo for the treatment of depression in older adults.
- Trial name
- LMIL (NCT02466958)
- Testing
- levomilnacipran
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of California, Los Angeles
Major Depressive Disorder, Dysthymic Disorder
Antidepressant Response in the Treatment of Depressive Symptoms and Frailty Characteristics in Older Adults
The goal of this open-administration treatment study of citalopram (or duloxetine) is to evaluate the effect of antidepressant medication on treating the syndrome of "frailty" in older adults with depressive symptoms.
- Conditions
- Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder, NOS
- Trial name
- NCT01973283
- Testing
- Antidepressant Medication
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder With Suicidal Ideation With Intent
Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent
Study of efficacy and safety of MIJ821 in addition to comprehensive standard of care on the rapid reduction of symptoms of Major Depressive Disorder (MDD) in subjects who have suicidal ideation with intent
- Trial name
- NCT04722666
- Testing
- MIJ821 Intravenous Injection
- Where
- 39 sites in United States, Argentina and 12 more
- Volunteers
- 199 people
- Sponsor
- Novartis Pharmaceuticals
Major Depressive Disorder, Insomnia
A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia
This study is a randomized, double-blind, placebo-controlled study of the safety, tolerability, and efficacy of SAGE-217 compared to placebo in adult participants with comorbid major depressive disorder (MDD) and insomnia.
- Trial name
- NCT03771664
- Testing
- SAGE-217
- Where
- 28 sites in United States
- Volunteers
- 87 people
- Sponsor
- Biogen
HIV Infections, Fatigue
Effectiveness of Modafinil for Treating Fatigue in Adults With HIV/AIDS
This study will determine whether modafinil (Provigil®), a medication approved for the treatment of narcolepsy, is effective in reducing fatigue in adults with HIV/AIDS.
- Trial name
- NCT00118378
- Testing
- Modafinil
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- New York State Psychiatric Institute